Skip to main content

Efficacy and Safety Results from BE OPTIMAL in PsA

Nov 21, 2022 9:34 am

Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA. L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×